Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Wong, Nathan D. (7202836669)"

Filter results by typing the first few letters
Now showing 1 - 9 of 9
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Lipid lowering nutraceuticals in clinical practice: Position paper from an International Lipid Expert Panel
    (2017)
    Cicero, Arrigo F.G. (7003403707)
    ;
    Colletti, Alessandro (56538296200)
    ;
    Bajraktari, Gani (12764374400)
    ;
    Descamps, Olivier (6701764714)
    ;
    Djuric, Dragan M. (36016317400)
    ;
    Ezhov, Marat (57218254057)
    ;
    Fras, Zlatko (35615293100)
    ;
    Katsiki, Niki (25421628400)
    ;
    Langlois, Michel (56355464300)
    ;
    Latkovskis, Gustavs (6507756746)
    ;
    Panagiotakos, Demosthenes B. (7005977027)
    ;
    Paragh, Gyorgy (7003269524)
    ;
    Mikhailidis, Dimitri P. (36042757800)
    ;
    Mitchenko, Olena (57193516360)
    ;
    Paulweber, Bernhard (36519500600)
    ;
    Pella, Daniel (57207570055)
    ;
    Pitsavos, Christos (35399739300)
    ;
    Reiner, Željko (55411641000)
    ;
    Ray, Kausik K. (35303190300)
    ;
    Rizzo, Manfredi (7202023733)
    ;
    Sahebkar, Amirhossein (26639699900)
    ;
    Serban, Maria-Corina (56497645100)
    ;
    Sperling, Laurence S. (56785421900)
    ;
    Toth, Peter P. (7102285226)
    ;
    Vinereanu, Dragos (6603080279)
    ;
    Vrablík, Michal (6701669648)
    ;
    Wong, Nathan D. (7202836669)
    ;
    Banach, Maciej (22936699500)
    [No abstract available]
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Lipid-lowering nutraceuticals in clinical practice: Position paper from an International Lipid Expert Panel
    (2017)
    Cicero, Arrigo F.G. (7003403707)
    ;
    Colletti, Alessandro (56538296200)
    ;
    Bajraktari, Gani (12764374400)
    ;
    Descamps, Olivier (6701764714)
    ;
    Djuric, Dragan M. (36016317400)
    ;
    Ezhov, Marat (57218254057)
    ;
    Fras, Zlatko (35615293100)
    ;
    Katsiki, Niki (25421628400)
    ;
    Langlois, Michel (56355464300)
    ;
    Latkovskis, Gustavs (6507756746)
    ;
    Panagiotakos, Demosthenes B. (7005977027)
    ;
    Paragh, Gyorgy (7003269524)
    ;
    Mikhailidis, Dimitri P. (36042757800)
    ;
    Mitchenko, Olena (57193516360)
    ;
    Paulweber, Bernhard (36519500600)
    ;
    Pella, Daniel (57207570055)
    ;
    Pitsavos, Christos (35399739300)
    ;
    Reiner, Željko (55411641000)
    ;
    Ray, Kausik K. (35303190300)
    ;
    Rizzo, Manfredi (7202023733)
    ;
    Sahebkar, Amirhossein (26639699900)
    ;
    Serban, Maria-Corina (56497645100)
    ;
    Sperling, Laurence S. (56785421900)
    ;
    Toth, Peter P. (7102285226)
    ;
    Vinereanu, Dragos (6603080279)
    ;
    Vrablík, Michal (6701669648)
    ;
    Wong, Nathan D. (7202836669)
    ;
    Banach, Maciej (22936699500)
    In recent years, there has been growing interest in the possible use of nutraceuticals to improve and optimize dyslipidemia control and therapy. Based on the data from available studies, nutraceuticals might help patients obtain theraputic lipid goals and reduce cardiovascular residual risk. Some nutraceuticals have essential lipidlowering properties confirmed in studies; some might also have possible positive effects on nonlipid cardiovascular risk factors and have been shown to improve early markers of vascular health such as endothelial function and pulse wave velocity. However, the clinical evidence supporting the use of a single lipid-lowering nutraceutical or a combination of them is largely variable and, for many of the nutraceuticals, the evidence is very limited and, therefore, often debatable. The purpose of this position paper is to provide consensus-based recommendations for the optimal use of lipid-lowering nutraceuticals to manage dyslipidemia in patients who are still not on statin therapy, patients who are on statin or combination therapy but have not achieved lipid goals, and patients with statin intolerance. This statement is intended for physicians and other healthcare professionals engaged in the diagnosis and management of patients with lipid disorders, especially in the primary care setting. © The Author(s) 2017. Published by Oxford University Press on behalf of the International Life Sciences Institute. All rights reserved.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Post-trauma cardiovascular risk factors and subclinical atherosclerosis in young adults following the war in Bosnia and Herzegovina; [波斯尼亚和黑塞哥维那战争后青年的创伤后心血管危险因素和亚临床动脉粥样硬化]; [Factores de riesgo cardiovascular y ateroesclerosis subclínica post-trauma en adultos jóvenes luego de la guerra en Bosnia y Herzegovina]
    (2019)
    Vulic, Dusko (55900752200)
    ;
    Secerov Zecevic, Drenka (55596933700)
    ;
    Burgic, Marija (57209574865)
    ;
    Vujkovic, Zoran (6503905037)
    ;
    Ristic, Sinisa (17136405900)
    ;
    Marinkovic, Jelena (7004611210)
    ;
    Medenica, Snezana (57191865365)
    ;
    Wong, Nathan D. (7202836669)
    Background: Risk of cardiovascular disease (CVD) has been associated with stress from serving in a war, but it has not been established whether children who experience war-related stress are at increased CVD risk. Objective: This study aimed to compare CVD risk factors in young adults according to whether they experienced traumatic events as children during the 1990–1995 war in Bosnia and Herzegovina, and whether those exposed to trauma have evidence of subclinical atherosclerosis. Method: We examined 372 first-year medical students who were preschool children during the war (1990–1995) (average age 19.5 ± 1.7 years, 67% female) in 2007–2010. They completed the Semi-Structured Interview for Survivors of War. CVD risk factors and carotid intima–media thickness (CIMT) measurements were obtained and compared in individuals with and without trauma. We also examined whether increased CIMT was independently associated with trauma after adjustment for other risk factors. Results: From multiple logistic regression, only elevated triglycerides (> 1.7 mmol/l) were associated with a 5.2 greater odds of having experienced trauma. The mean CIMT of subjects with trauma was greater than that of non-trauma-exposed subjects (0.53 mm vs 0.50 mm, p = 0.07). Moreover, trauma was independently associated with higher CIMT (difference = 0.036 mm, p = 0.024) after adjustment for CVD risk factors. Conclusions: We show that most CVD risk factors are associated with post-war trauma in young adults, and, if present, such trauma is associated with higher triglycerides and higher levels of CIMT in multivariable analysis. © 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Risk factor indicators in offspring of patients with premature coronary heart disease in Banja Luka region/Republic of Srpska/Bosnia and Herzegovina
    (2016)
    Vulic, Dusko (55900752200)
    ;
    Loncar, Sasa (6506737514)
    ;
    Ostojic, Miodrag (34572650500)
    ;
    Marinkovic, Jelena (7004611210)
    ;
    Vulic, Branka (57190089393)
    ;
    Wong, Nathan D. (7202836669)
    Introduction: Risk factor differences among offspring of patients with premature coronary heart disease (CHD) have not been widely studiem. Material and methods: We examined 161 persons from the region of Banja Luka, including 81 children (mean age: 25.9 years, 45.7% female) with a history of CHD and a control group of 80 persons (mean age: 24.1, 50% female). Medical history interviews and risk factor measurements were performed. Results: There were differences in mean body amss index (BMI) (26.1 kg/m2 vs. 23.1 kg/m2, p < 0.0001), waist circumference (87.7 cm vs. 83.9 cm, p = 0.002), hip circumference (99.3 cm vs. 95.84 cm, p < 0.002), systolic blood pressure (BP) (128.09 mm Hg vs. 122.7 mm Hg, p = 0.007), and diastolic BP (99.3 mm Hg vs. 95.8 mm Hg, p = 0.07). Moreover, HDL-cholesterol was significantly lower (1.1 mmol/l vs. 1.4 mmol/l, p = 0.0001), triglycerides significantly higher (2.2 mmol/l vs. 1.6 mmol/l, p = 0.001), and TC/HDL-ratio was significantly higher (5.1 vs. 4.0, p < 0.001) comparing cases and controls, respectively, adjusted for age, gender, and standard CHD risk factors total cholesterol, LDL and HDL cholesterol, smoking, systolic and diastolic BP, and BMI, those with HDL-C > 1.0 mmol/l in men and 1.2 mmol/l in women had a reduced odds (OR = 0.08, 95% CI: 0.02-0.34 of CHD as well as those with change of fat type (OR = 0.26, 95% CI: 0.11-0.60). Conclusions: Children of parents with premature CHD have a significantly greater burden of CHD risk factors, with low HDL-C, in particular, being associated with an increased likelihood of being a child of a parent with premature CHD. © 2016 Termedia & Banach.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Statin intolerance - An attempt at a unified definition. Position paper from an International Lipid Expert Panel
    (2015)
    Banach, Maciej (22936699500)
    ;
    Rizzo, Manfredi (7202023733)
    ;
    Toth, Peter P. (7102285226)
    ;
    Farnier, Michel (7003571530)
    ;
    Davidson, Michael H. (7401857573)
    ;
    Al-Rasadi, Khalid (37028026100)
    ;
    Aronow, Wilbert S. (36047427700)
    ;
    Athyros, Vasilis (7005230222)
    ;
    Djuric, Dragan M. (36016317400)
    ;
    Ezhov, Marat V. (57218254057)
    ;
    Greenfield, Robert S. (56556223900)
    ;
    Hovingh, G. Kees (6602780482)
    ;
    Kostner, Karam (7004449333)
    ;
    Serban, Corina (56497645100)
    ;
    Lighezan, Daniel (8245777800)
    ;
    Fras, Zlatko (35615293100)
    ;
    Moriarty, Patrick M. (7006056255)
    ;
    Muntner, Paul (7003615149)
    ;
    Goudev, Assen (58395505000)
    ;
    Ceska, Richard (7005272416)
    ;
    Nicholls, Stephen J. (7007131964)
    ;
    Broncel, Marlena (6507507565)
    ;
    Nikolic, Dragana (48061331700)
    ;
    Pella, Daniel (57207570055)
    ;
    Puri, Raman (9433943200)
    ;
    Rysz, Jacek (7004232269)
    ;
    Wong, Nathan D. (7202836669)
    ;
    Bajnok, Laszlo (6602851367)
    ;
    Jones, Steven R. (55585941500)
    ;
    Ray, Kausik K. (35303190300)
    ;
    Mikhailidis, Dimitri P. (36042757800)
    Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are musclerelated. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10-15% of patients. In clinical practice, statin intolerance limits effective treatment of patients at risk of, or with, cardiovascular disease. Knowledge of the most common adverse effects of statin therapy that might cause statin intolerance and the clear definition of this phenomenon is crucial to effectively treat patients with lipid disorders. Therefore, the aim of this position paper was to suggest a unified definition of statin intolerance, and to complement the recent EAS statement on SAMS, where the pathophysiology, diagnosis and the management were comprehensively presented. Copyright © 2015 Termedia & Banach.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Statin intolerance-an attempt at a unified definition. Position paper from an International Lipid Expert Panel
    (2015)
    Banach, Maciej (22936699500)
    ;
    Rizzo, Manfredi (7202023733)
    ;
    Toth, Peter P. (7102285226)
    ;
    Farnier, Michel (7003571530)
    ;
    Davidson, Michael H. (7401857573)
    ;
    Al-Rasadi, Khalid (37028026100)
    ;
    Aronow, Wilbert S. (36047427700)
    ;
    Athyros, Vasilis (7005230222)
    ;
    Djuric, Dragan M. (36016317400)
    ;
    Ezhov, Marat V. (57218254057)
    ;
    Greenfield, Robert S. (56556223900)
    ;
    Hovingh, G. Kees (6602780482)
    ;
    Kostner, Karam (7004449333)
    ;
    Serban, Corina (56497645100)
    ;
    Lighezan, Daniel (8245777800)
    ;
    Fras, Zlatko (35615293100)
    ;
    Moriarty, Patrick M. (7006056255)
    ;
    Muntner, Paul (7003615149)
    ;
    Goudev, Assen (58395505000)
    ;
    Ceska, Richard (7005272416)
    ;
    Nicholls, Stephen J. (7007131964)
    ;
    Broncel, Marlena (6507507565)
    ;
    Nikolic, Dragana (48061331700)
    ;
    Pella, Daniel (57207570055)
    ;
    Puri, Raman (9433943200)
    ;
    Rysz, Jacek (7004232269)
    ;
    Wong, Nathan D. (7202836669)
    ;
    Bajnok, Laszlo (6602851367)
    ;
    Jones, Steven R. (55585941500)
    ;
    Ray, Kausik K. (35303190300)
    ;
    Mikhailidis, Dimitri P. (36042757800)
    Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10-15% of patients.In clinical practice, statin intolerance limits effective treatment of patients at risk of, or with, cardiovascular disease. Knowledge of the most common adverse effects of statin therapy that might cause statin intolerance and the clear definition of this phenomenon is crucial to effectively treat patients with lipid disorders. Therefore, the aim of this position paper was to suggest a unified definition of statin intolerance, and to complement the recent EAS statement on SAMS, where the pathophysiology, diagnosis and the management were comprehensively presented. © 2015 Informa UK, Ltd.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP)
    (2021)
    Zhubi-Bakija, Fjolla (57217489853)
    ;
    Bajraktari, Gani (12764374400)
    ;
    Bytyçi, Ibadete (56166743400)
    ;
    Mikhailidis, Dimitri P. (36042757800)
    ;
    Henein, Michael Y. (7006300845)
    ;
    Latkovskis, Gustavs (6507756746)
    ;
    Rexhaj, Zarife (57201468540)
    ;
    Zhubi, Esra (57217491805)
    ;
    Banach, Maciej (22936699500)
    ;
    Alnouri, Fahad (56166712200)
    ;
    Amar, Fahma (57216210412)
    ;
    Atanasov, Atanas G. (7102991067)
    ;
    Bartlomiejczyk, Marcin A. (57201880628)
    ;
    Bjelakovic, Bojko (15070010000)
    ;
    Bruckert, Eric (55539414500)
    ;
    Cafferata, Alberto (55820685700)
    ;
    Ceska, Richard (7005272416)
    ;
    Cicero, Arrigo F.G. (7003403707)
    ;
    Collet, Xavier (7004040078)
    ;
    Descamps, Olivier (6701764714)
    ;
    Djuric, Dragan (36016317400)
    ;
    Durst, Ronen (7005127717)
    ;
    Ezhov, Marat V. (57218254057)
    ;
    Fras, Zlatko (35615293100)
    ;
    Gaita, Dan (26537386100)
    ;
    Hernandez, Adrian V. (56447777300)
    ;
    Jones, Steven R. (55585941500)
    ;
    Jozwiak, Jacek (21833993700)
    ;
    Kakauridze, Nona (14052213500)
    ;
    Katsiki, Niki (25421628400)
    ;
    Khera, Amit (8240985600)
    ;
    Kostner, Karam (7004449333)
    ;
    Kubilius, Raimondas (12779626300)
    ;
    Mancini, G.B. John (8988367800)
    ;
    Marais, A. David (7005986976)
    ;
    Martin, Seth S. (55450099100)
    ;
    Martinez, Julio Acosta (59598120300)
    ;
    Mazidi, Mohsen (57200232563)
    ;
    Mirrakhimov, Erkin (57216202888)
    ;
    Miserez, Andre R. (57260096800)
    ;
    Mitchenko, Olena (57193516360)
    ;
    Moriarty, Patrick M. (7006056255)
    ;
    Nabavi, Seyed Mohammad (55621554100)
    ;
    Nair, Devaki (7005754649)
    ;
    Panagiotakos, Demosthenes B. (7005977027)
    ;
    Paragh, György (7003269524)
    ;
    Pella, Daniel (57207570055)
    ;
    Penson, Peter E. (6506734112)
    ;
    Petrulioniene, Zaneta (24482298700)
    ;
    Pirro, Matteo (22036502300)
    ;
    Postadzhiyan, Arman (55900865700)
    ;
    Puri, Raman (9433943200)
    ;
    Reda, Ashraf (36700243800)
    ;
    Reiner, Željko (55411641000)
    ;
    Riadh, Jemaa (6508252624)
    ;
    Richter, Dimitri (35434226200)
    ;
    Rizzo, Manfredi (7202023733)
    ;
    Ruscica, Massimiliano (6506814092)
    ;
    Sahebkar, Amirhossein (26639699900)
    ;
    Sattar, Naveed (7007043802)
    ;
    Serban, Maria-Corina (56497645100)
    ;
    Shehab, Abdulla M.A. (6603838351)
    ;
    Shek, Aleksandr B. (57205032006)
    ;
    Sirtori, Cesare R. (57203252370)
    ;
    Stefanutti, Claudia (56055363600)
    ;
    Tomasik, Tomasz (6602445472)
    ;
    Toth, Peter P. (7102285226)
    ;
    Viigimaa, Margus (57221665512)
    ;
    Vinereanu, Dragos (6603080279)
    ;
    Vohnout, Branislav (6602372073)
    ;
    von Haehling, Stephan (6602981479)
    ;
    Vrablik, Michal (6701669648)
    ;
    Wong, Nathan D. (7202836669)
    ;
    Yeh, Hung-I. (7401745306)
    ;
    Zhisheng, Jiang (57204466187)
    ;
    Zirlik, Andreas (57193916052)
    Proteins play a crucial role in metabolism, in maintaining fluid and acid-base balance and antibody synthesis. Dietary proteins are important nutrients and are classified into: 1) animal proteins (meat, fish, poultry, eggs and dairy), and, 2) plant proteins (legumes, nuts and soy). Dietary modification is one of the most important lifestyle changes that has been shown to significantly decrease the risk of cardiovascular (CV) disease (CVD) by attenuating related risk factors. The CVD burden is reduced by optimum diet through replacement of unprocessed meat with low saturated fat, animal proteins and plant proteins. In view of the available evidence, it has become acceptable to emphasize the role of optimum nutrition to maintain arterial and CV health. Such healthy diets are thought to increase satiety, facilitate weight loss, and improve CV risk. Different studies have compared the benefits of omnivorous and vegetarian diets. Animal protein related risk has been suggested to be greater with red or processed meat over and above poultry, fish and nuts, which carry a lower risk for CVD. In contrast, others have shown no association of red meat intake with CVD. The aim of this expert opinion recommendation was to elucidate the different impact of animal vs vegetable protein on modifying cardiometabolic risk factors. Many observational and interventional studies confirmed that increasing protein intake, especially plant-based proteins and certain animal-based proteins (poultry, fish, unprocessed red meat low in saturated fats and low-fat dairy products) have a positive effect in modifying cardiometabolic risk factors. Red meat intake correlates with increased CVD risk, mainly because of its non-protein ingredients (saturated fats). However, the way red meat is cooked and preserved matters. Thus, it is recommended to substitute red meat with poultry or fish in order to lower CVD risk. Specific amino acids have favourable results in modifying major risk factors for CVD, such as hypertension. Apart from meat, other animal-source proteins, like those found in dairy products (especially whey protein) are inversely correlated to hypertension, obesity and insulin resistance. © 2020 The Author(s)
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP)
    (2021)
    Zhubi-Bakija, Fjolla (57217489853)
    ;
    Bajraktari, Gani (12764374400)
    ;
    Bytyçi, Ibadete (56166743400)
    ;
    Mikhailidis, Dimitri P. (36042757800)
    ;
    Henein, Michael Y. (7006300845)
    ;
    Latkovskis, Gustavs (6507756746)
    ;
    Rexhaj, Zarife (57201468540)
    ;
    Zhubi, Esra (57217491805)
    ;
    Banach, Maciej (22936699500)
    ;
    Alnouri, Fahad (56166712200)
    ;
    Amar, Fahma (57216210412)
    ;
    Atanasov, Atanas G. (7102991067)
    ;
    Bartlomiejczyk, Marcin A. (57201880628)
    ;
    Bjelakovic, Bojko (15070010000)
    ;
    Bruckert, Eric (55539414500)
    ;
    Cafferata, Alberto (55820685700)
    ;
    Ceska, Richard (7005272416)
    ;
    Cicero, Arrigo F.G. (7003403707)
    ;
    Collet, Xavier (7004040078)
    ;
    Descamps, Olivier (6701764714)
    ;
    Djuric, Dragan (36016317400)
    ;
    Durst, Ronen (7005127717)
    ;
    Ezhov, Marat V. (57218254057)
    ;
    Fras, Zlatko (35615293100)
    ;
    Gaita, Dan (26537386100)
    ;
    Hernandez, Adrian V. (56447777300)
    ;
    Jones, Steven R. (55585941500)
    ;
    Jozwiak, Jacek (21833993700)
    ;
    Kakauridze, Nona (14052213500)
    ;
    Katsiki, Niki (25421628400)
    ;
    Khera, Amit (8240985600)
    ;
    Kostner, Karam (7004449333)
    ;
    Kubilius, Raimondas (12779626300)
    ;
    Mancini, G.B. John (8988367800)
    ;
    Marais, A. David (7005986976)
    ;
    Martin, Seth S. (55450099100)
    ;
    Martinez, Julio Acosta (59598120300)
    ;
    Mazidi, Mohsen (57200232563)
    ;
    Mirrakhimov, Erkin (57216202888)
    ;
    Miserez, Andre R. (57260096800)
    ;
    Mitchenko, Olena (57193516360)
    ;
    Moriarty, Patrick M. (7006056255)
    ;
    Nabavi, Seyed Mohammad (55621554100)
    ;
    Nair, Devaki (7005754649)
    ;
    Panagiotakos, Demosthenes B. (7005977027)
    ;
    Paragh, György (7003269524)
    ;
    Pella, Daniel (57207570055)
    ;
    Penson, Peter E. (6506734112)
    ;
    Petrulioniene, Zaneta (24482298700)
    ;
    Pirro, Matteo (22036502300)
    ;
    Postadzhiyan, Arman (55900865700)
    ;
    Puri, Raman (9433943200)
    ;
    Reda, Ashraf (36700243800)
    ;
    Reiner, Željko (55411641000)
    ;
    Riadh, Jemaa (6508252624)
    ;
    Richter, Dimitri (35434226200)
    ;
    Rizzo, Manfredi (7202023733)
    ;
    Ruscica, Massimiliano (6506814092)
    ;
    Sahebkar, Amirhossein (26639699900)
    ;
    Sattar, Naveed (7007043802)
    ;
    Serban, Maria-Corina (56497645100)
    ;
    Shehab, Abdulla M.A. (6603838351)
    ;
    Shek, Aleksandr B. (57205032006)
    ;
    Sirtori, Cesare R. (57203252370)
    ;
    Stefanutti, Claudia (56055363600)
    ;
    Tomasik, Tomasz (6602445472)
    ;
    Toth, Peter P. (7102285226)
    ;
    Viigimaa, Margus (57221665512)
    ;
    Vinereanu, Dragos (6603080279)
    ;
    Vohnout, Branislav (6602372073)
    ;
    von Haehling, Stephan (6602981479)
    ;
    Vrablik, Michal (6701669648)
    ;
    Wong, Nathan D. (7202836669)
    ;
    Yeh, Hung-I. (7401745306)
    ;
    Zhisheng, Jiang (57204466187)
    ;
    Zirlik, Andreas (57193916052)
    Proteins play a crucial role in metabolism, in maintaining fluid and acid-base balance and antibody synthesis. Dietary proteins are important nutrients and are classified into: 1) animal proteins (meat, fish, poultry, eggs and dairy), and, 2) plant proteins (legumes, nuts and soy). Dietary modification is one of the most important lifestyle changes that has been shown to significantly decrease the risk of cardiovascular (CV) disease (CVD) by attenuating related risk factors. The CVD burden is reduced by optimum diet through replacement of unprocessed meat with low saturated fat, animal proteins and plant proteins. In view of the available evidence, it has become acceptable to emphasize the role of optimum nutrition to maintain arterial and CV health. Such healthy diets are thought to increase satiety, facilitate weight loss, and improve CV risk. Different studies have compared the benefits of omnivorous and vegetarian diets. Animal protein related risk has been suggested to be greater with red or processed meat over and above poultry, fish and nuts, which carry a lower risk for CVD. In contrast, others have shown no association of red meat intake with CVD. The aim of this expert opinion recommendation was to elucidate the different impact of animal vs vegetable protein on modifying cardiometabolic risk factors. Many observational and interventional studies confirmed that increasing protein intake, especially plant-based proteins and certain animal-based proteins (poultry, fish, unprocessed red meat low in saturated fats and low-fat dairy products) have a positive effect in modifying cardiometabolic risk factors. Red meat intake correlates with increased CVD risk, mainly because of its non-protein ingredients (saturated fats). However, the way red meat is cooked and preserved matters. Thus, it is recommended to substitute red meat with poultry or fish in order to lower CVD risk. Specific amino acids have favourable results in modifying major risk factors for CVD, such as hypertension. Apart from meat, other animal-source proteins, like those found in dairy products (especially whey protein) are inversely correlated to hypertension, obesity and insulin resistance. © 2020 The Author(s)
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    The Role of Nutraceuticals in Statin Intolerant Patients
    (2018)
    Banach, Maciej (22936699500)
    ;
    Patti, Angelo Maria (16432525100)
    ;
    Giglio, Rosaria Vincenza (55645572700)
    ;
    Cicero, Arrigo F.G. (7003403707)
    ;
    Atanasov, Atanas G. (7102991067)
    ;
    Bajraktari, Gani (12764374400)
    ;
    Bruckert, Eric (55539414500)
    ;
    Descamps, Olivier (6701764714)
    ;
    Djuric, Dragan M. (36016317400)
    ;
    Ezhov, Marat (57218254057)
    ;
    Fras, Zlatko (35615293100)
    ;
    von Haehling, Stephan (6602981479)
    ;
    Katsiki, Niki (25421628400)
    ;
    Langlois, Michel (56355464300)
    ;
    Latkovskis, Gustavs (6507756746)
    ;
    Mancini, G.B. John (8988367800)
    ;
    Mikhailidis, Dimitri P. (36042757800)
    ;
    Mitchenko, Olena (57193516360)
    ;
    Moriarty, Patrick M. (7006056255)
    ;
    Muntner, Paul (7003615149)
    ;
    Nikolic, Dragana (48061331700)
    ;
    Panagiotakos, Demosthenes B. (7005977027)
    ;
    Paragh, Gyorgy (7003269524)
    ;
    Paulweber, Bernhard (36519500600)
    ;
    Pella, Daniel (57207570055)
    ;
    Pitsavos, Christos (35399739300)
    ;
    Reiner, Željko (55411641000)
    ;
    Rosano, Giuseppe M.C. (7007131876)
    ;
    Rosenson, Robert S. (7006279584)
    ;
    Rysz, Jacek (7004232269)
    ;
    Sahebkar, Amirhossein (26639699900)
    ;
    Serban, Maria-Corina (56497645100)
    ;
    Vinereanu, Dragos (6603080279)
    ;
    Vrablík, Michal (6701669648)
    ;
    Watts, Gerald F. (57210953292)
    ;
    Wong, Nathan D. (7202836669)
    ;
    Rizzo, Manfredi (7202023733)
    Statins are the most common drugs administered for patients with cardiovascular disease. However, due to statin-associated muscle symptoms, adherence to statin therapy is challenging in clinical practice. Certain nutraceuticals, such as red yeast rice, bergamot, berberine, artichoke, soluble fiber, and plant sterols and stanols alone or in combination with each other, as well as with ezetimibe, might be considered as an alternative or add-on therapy to statins, although there is still insufficient evidence available with respect to long-term safety and effectiveness on cardiovascular disease prevention and treatment. These nutraceuticals could exert significant lipid-lowering activity and might present multiple non–lipid-lowering actions, including improvement of endothelial dysfunction and arterial stiffness, as well as anti-inflammatory and antioxidative properties. The aim of this expert opinion paper is to provide the first attempt at recommendation on the management of statin intolerance through the use of nutraceuticals with particular attention on those with effective low-density lipoprotein cholesterol reduction. © 2018 American College of Cardiology Foundation

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback